Prevention of chemotherapy-induced ovarian failure with goserelin in premenopausal lymphoma patients

المؤلفون المشاركون

al-Shayma, Ibrahim Rabi
al-Barri, Ahmad abd allah
Shaban, Ahmad Hasan
Husayn, Raghdah R. S.

المصدر

Bahrain Medical Bulletin

العدد

المجلد 43، العدد 2 (30 يونيو/حزيران 2021)، ص ص. 463-470، 8ص.

الناشر

مستشفى الملك حمد الجامعي

تاريخ النشر

2021-06-30

دولة النشر

البحرين

عدد الصفحات

8

التخصصات الرئيسية

علم الصيدلة

الملخص EN

Purpose : To determine the effectiveness of gonadotropin-releasing hormone agonist (GnRHa) (Goserelin acetate) in preserving ovarian function in premenopausal women undergoing combined chemotherapy for Hodgkin or non-Hodgkin lymphoma by documenting the changes in hormonal levels.

Design : Prospective randomized controlled study.

Setting : Oncology Department, Beni-Suef University Hospital, Beni-Suef, Egypt.

Methods : Fifty-two females aged 17-40 years old were assigned at random to receive combined GnRHa (Goserelin acetate) and standard chemotherapy for 6 months (goserelin group, n = 26), or standard chemotherapy alone (control group, n = 26).

Goserelin (3.6 mg) was given subcutaneously at the start of chemotherapy every 4 weeks for 6 months.

The levels of follicle stimulating hormone (FSH) and Estradiol (E2) were measured at 3 and 6 months (6-8 cycles) during the chemotherapy regimen and 3 months after, AMH anti-Mullerian hormone was measured at base line and end of follow up, also assessment of clinical history (menstrual rhythm).

In addition, side effects were observed and recorded during therapy and overall response to the treatment.

Results : The goserelin group showed significantly lower FSH levels compared to the control group at 3 and 6 months of treatment and after 3 months of chemotherapy, and higher menstrual recovery percentage after completion chemotherapy, also better higher ovarian reserve.

However, the E2 level was not significantly different between groups.

The occurrence of adverse events was similar in both groups, and there was no significant difference in overall response to the treatment at the end of follow-up.

Conclusion : In young females, concurrent administration of goserelin acetate during chemotherapy may preserve ovarian function, with a mean FSH level <10 IU/L and protect from premature ovarian failure (POF).

However, a long-term study is required to further validate these findings.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

al-Shayma, Ibrahim Rabi& al-Barri, Ahmad abd allah& Shaban, Ahmad Hasan& Husayn, Raghdah R. S.. 2021. Prevention of chemotherapy-induced ovarian failure with goserelin in premenopausal lymphoma patients. Bahrain Medical Bulletin،Vol. 43, no. 2, pp.463-470.
https://search.emarefa.net/detail/BIM-1493219

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

al-Barri, Ahmad abd allah…[et al.]. Prevention of chemotherapy-induced ovarian failure with goserelin in premenopausal lymphoma patients. Bahrain Medical Bulletin Vol. 43, no. 2 (Jun. 2021), pp.463-470.
https://search.emarefa.net/detail/BIM-1493219

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

al-Shayma, Ibrahim Rabi& al-Barri, Ahmad abd allah& Shaban, Ahmad Hasan& Husayn, Raghdah R. S.. Prevention of chemotherapy-induced ovarian failure with goserelin in premenopausal lymphoma patients. Bahrain Medical Bulletin. 2021. Vol. 43, no. 2, pp.463-470.
https://search.emarefa.net/detail/BIM-1493219

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references : p. 469-470

رقم السجل

BIM-1493219